Interleukin‑33‑induced immune tolerance is associated with the imbalance of memory and naïve T‑lymphocyte subsets

Shi,Xu; Tang,Ying; Sun,Xiguang; Liu,Yufei; Sun,Ying; Sun,Munan; Jiang,Yanfang; Li,Yulin

doi:10.3892/mmr.2016.5844

Interleukin‑33‑induced immune tolerance is associated with the imbalance of memory and naïve T‑lymphocyte subsets

Authors:
- Xu Shi
- Ying Tang
- Xiguang Sun
- Yufei Liu
- Ying Sun
- Munan Sun
- Yanfang Jiang
- Yulin Li
View Affiliations

Affiliations: The Key Laboratory of Pathobiology, Ministry of Education, College of Basic Medical Sciences, Jilin University, Changchun, Jilin 130000, P.R. China, Department of Respiration, The First Hospital, Jilin University, Changchun, Jilin 130032, P.R. China, Department of Hand Surgery, The First Hospital, Jilin University, Changchun, Jilin 130032, P.R. China, Department of Pediatric ICU, The First Hospital, Jilin University, Changchun, Jilin 130032, P.R. China, Department of Dermatology, The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, Jilin 130000, P.R. China, Cancer Biotherapy Center, Jilin Province People's Hospital, Changchun, Jilin 130000, P.R. China, Central Laboratory, The First Hospital, Jilin University, Changchun, Jilin 130032, P.R. China
Published online on: October 13, 2016 https://doi.org/10.3892/mmr.2016.5844
Pages: 4837-4843

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The current study aimed to investigate the distribution of memory and naïve T cell (TN) subsets in hepatitis B virus (HBV)‑infected patients at different immune stages and investigate the effect of interleukin 33 (IL‑33) on the regulation of the T‑cell subsets. The distributions of memory and naïve T cells were detected by flow cytometry. ELISA was conducted to assess the levels of IL‑4, IL‑5, IL‑10, IL‑12, interferon γ and tumor necrosis factor α. The expression levels of IL‑33 and HBV x protein (HBx) were measured by reverse transcription‑quantitative polymerase chain reaction and western blot analysis, respectively. By detecting TNs, central memory T cells (TCM) and effector memory T cells (TEM), it was identified that the proportions of TCM and TEM in CD4+ T cells were increased in patients with HBV. The trend observed for levels of CD8+ TCM and TEM was similar to that of CD4+ T cells in the immune tolerance and immune activation groups, however CD8+ TCM and TEM were significantly reduced in patients who underwent treatment. The CD8+ TEM cells appeared to be more sensitive to HBV activation and drug therapy. In addition, IL‑33 stimulation was observed to induce imbalances of CD8+ TN and CD8+ TEM, and while the imbalances were directly regulated by HBx, IL‑33 was not a key factor for the expression of HBx. CD8+ TEM cells may be a sensitive marker to assess the immune state of patients with HBV and the effect of clinical therapy. Treatment targeting IL‑33 may be a potential method to reverse HBV‑induced immune tolerance.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Zender L, Villanueva A, Tovar V, Sia D, Chiang DY and Llovet JM: Cancer gene discovery in hepatocellular carcinoma. J Hepatol. 52:921–929. 2010. View Article : Google Scholar : PubMed/NCBI
3	Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y and Kakizoe T: Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomised trial. Lancet. 356:802–807. 2000. View Article : Google Scholar : PubMed/NCBI
4	Singal AG, Nehra M, Adams-Huet B, Yopp AC, Tiro JA, Marrero JA, Lok AS and Lee WM: Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: Where did surveillance fail? Am J Gastroenterol. 108:425–432. 2013. View Article : Google Scholar : PubMed/NCBI
5	Bréchot C: Pathogenesis of hepatitis B virus related hepatocellular carcinoma: Old and new paradigms. Gastroenterology. 127(5): Suppl 1. S56–S61. 2004. View Article : Google Scholar : PubMed/NCBI
6	Tanaka T, Bai Z, Srinoulprasert Y, Yang BG, Hayasaka H and Miyasaka M: Chemokines in tumor progression and metastasis. Cancer Sci. 96:317–322. 2005. View Article : Google Scholar : PubMed/NCBI
7	Jain RK: Normalizing tumor microenvironment to treat cancer: Bench to bedside to biomarkers. J Clin Oncol. 31:2205–2218. 2013. View Article : Google Scholar : PubMed/NCBI
8	Moeini A, Cornellà H and Villanueva A: Emerging signaling pathways in hepatocellular carcinoma. Liver Cancer. 1:83–93. 2012. View Article : Google Scholar : PubMed/NCBI
9	Zheng S, Tansey WP, Hiebert SW and Zhao Z: Integrative network analysis identifies key genes and pathways in the progression of hepatitis C virus induced hepatocellular carcinoma. BMC Med Genomics. 4:622011. View Article : Google Scholar : PubMed/NCBI
10	Yin Y, Wu C, Song J, Wang J, Zhang E, Liu H, Yang D, Chen X, Lu M and Xu Y: DNA immunization with fusion of CTLA-4 to hepatitis B virus (HBV) core protein enhanced Th2 type responses and cleared HBV with an accelerated kinetic. PLoS One. 6:e225242011. View Article : Google Scholar : PubMed/NCBI
11	Barnaba V, Franco A, Paroli M, Benvenuto R, De Petrillo G, Burgio VL, Santilio I, Balsano C, Bonavita MS, Cappelli G, et al: Selective expansion of cytotoxic T lymphocytes with a CD4+ CD56+ surface phenotype and a T helper type 1 profile of cytokine secretion in the liver of patients chronically infected with hepatitis B virus. J Immunol. 152:3074–3087. 1994.PubMed/NCBI
12	Kang EH, Kown TY, Oh GT, Park WF, Park SI, Park SK and Lee YI: The flavonoid ellagic acid from a medicinal herb inhibits host immune tolerance induced by the hepatitis B virus-e antigen. Antiviral Res. 72:100–106. 2006. View Article : Google Scholar : PubMed/NCBI
13	Morrey JD, Motter NE, Chang S and Fairman J: Breaking B and T cell tolerance using cationic lipid-DNA complexes (CLDC) as a vaccine adjuvant with hepatitis B virus (HBV) surface antigen in transgenic mice expressing HBV. Antiviral Res. 90:227–230. 2011. View Article : Google Scholar : PubMed/NCBI
14	Ye B, Liu X, Li X, Kong H, Tian L and Chen Y: T-cell exhaustion in chronic hepatitis B infection: Current knowledge and clinical significance. Cell Death Dis. 6:e16942015. View Article : Google Scholar : PubMed/NCBI
15	Busca A and Kumar A: Innate immune responses in hepatitis B virus (HBV) infection. Virol J. 11:222014. View Article : Google Scholar : PubMed/NCBI
16	Kastenmuller W, Gasteiger G, Subramanian N, Sparwasser T, Busch DH, Belkaid Y, Drexler I and Germain RN: Regulatory T cells selectively control CD8+ T cell effector pool size via IL-2 restriction. J Immunol. 187:3186–3197. 2011. View Article : Google Scholar : PubMed/NCBI
17	Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, et al: IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 23:479–490. 2005. View Article : Google Scholar : PubMed/NCBI
18	Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L, Bouche G and Girard JP: IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA. 104:282–287. 2007. View Article : Google Scholar : PubMed/NCBI
19	Roussel L, Erard M, Cayrol C and Girard JP: Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. EMBO Rep. 9:1006–1012. 2008. View Article : Google Scholar : PubMed/NCBI
20	Vocca L, Di Sano C, Uasuf CG, Sala A, Riccobono L, Gangemi S, Albano GD, Bonanno A, Gagliardo R and Profita M: IL-33/ST2 axis controls Th2/IL-31 and Th17 immune response in allergic airway diseases. Immunobiology. 220:954–963. 2015. View Article : Google Scholar : PubMed/NCBI
21	Blom L and Poulsen LK: IL-1 family members IL-18 and IL-33 upregulate the inflammatory potential of differentiated human Th1 and Th2 cultures. J Immunol. 189:4331–4337. 2012. View Article : Google Scholar : PubMed/NCBI
22	Seki K, Sanada S, Kudinova AY, Steinhauser ML, Handa V, Gannon J and Lee RT: Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail. 2:684–691. 2009. View Article : Google Scholar : PubMed/NCBI
23	McLaren JE, Michael DR, Salter RC, Ashlin TG, Calder CJ, Miller AM, Liew FY and Ramji DP: IL-33 reduces macrophage foam cell formation. J Immunol. 185:1222–1229. 2010. View Article : Google Scholar : PubMed/NCBI
24	Wood IS, Wang B and Trayhurn P: IL-33, a recently identified interleukin-1 gene family member, is expressed in human adipocytes. Biochem Biophys Res Commun. 384:105–109. 2009. View Article : Google Scholar : PubMed/NCBI
25	Miller AM, Asquith DL, Hueber AJ, Anderson LA, Holmes WM, McKenzie AN, Xu D, Sattar N, McInnes IB and Liew FY: Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ Res. 107:650–658. 2010. View Article : Google Scholar : PubMed/NCBI
26	Arshad MI, Piquet-Pellorce C, L'Helgoualc'h A, Rauch M, Patrat-Delon S, Ezan F, Lucas-Clerc C, Nabti S, Lehuen A, Cubero FJ, et al: TRAIL but not FasL and TNFα, regulates IL-33 expression in murine hepatocytes during acute hepatitis. Hepatology. 56:2353–2362. 2012. View Article : Google Scholar : PubMed/NCBI
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
28	Xu X, Shang Q, Chen X, Nie W, Zou Z, Huang A, Meng M, Jin L, Xu R, Zhang JY, et al: Reversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patients. Cell Mol Immunol. 12:309–316. 2015. View Article : Google Scholar : PubMed/NCBI
29	Hojo-Souza NS, Pereira DB, Passos LS, Gazzinelli-Guimarães PH, Cardoso MS, Tada MS, Zanini GM, Bartholomeu DC, Fujiwara RT and Bueno LL: Phenotypic profiling of CD8(+) T cells during Plasmodium vivax blood-stage infection. BMC Infect Dis. 15:352015. View Article : Google Scholar : PubMed/NCBI
30	Kaech SM, Wherry EJ and Ahmed R: Effector and memory T-cell differentiation: Implications for vaccine development. Nat Rev Immunol. 2:251–262. 2002. View Article : Google Scholar : PubMed/NCBI
31	Wang J, Cai Y, Ji H, Feng J, Ayana DA, Niu J and Jiang Y: Serum IL-33 levels are associated with liver damage in patients with chronic hepatitis B. J Interferon Cytokine Res. 32:248–253. 2012. View Article : Google Scholar : PubMed/NCBI
32	Zhao PW, Shi X, Li C, Ayana DA, Niu JQ, Feng JY, Wang J and Jiang YF: IL-33 enhances humoral immunity against chronic HBV infection through activating CD4(+)CXCR5(+) TFH cells. J Interferon Cytokine Res. 35:454–463. 2015. View Article : Google Scholar : PubMed/NCBI
33	Neuveut C, Wei Y and Buendia MA: Mechanisms of HBV-related hepatocarcinogenesis. J Hepatol. 52:594–604. 2010. View Article : Google Scholar : PubMed/NCBI
34	Ng SA and Lee C: Hepatitis B virus X gene and hepatocarcinogenesis. J Gastroenterol. 46:974–990. 2011. View Article : Google Scholar : PubMed/NCBI